维生素D补充对伴有脂肪性肝炎的非酒精性脂肪肝患者肝脏纤维化因子的影响:随机临床试验研究方案
该研究方案计划招募46例非酒精性脂肪肝(NAFLD)患者,按性别和BMI区组匹配后随机分配至每日4000 IU维生素D组或安慰剂组,干预12周。主要检测血清维生素D受体、纤维化因子及纤维化微小RNA等指标,旨在评估维生素D补充对NAFLD患者肝纤维化的影响。
要点
- 拟招募46例NAFLD患者,随机接受4000 IU/日维生素D或安慰剂12周。
- 检测指标包括血清VDR、纤维化因子、纤维化MiR及肝酶等。
- 该试验为首个评估维生素D对NAFLD患者纤维化因子影响的随机对照试验。
核心结论
- 该方案旨在评估维生素D补充对NAFLD伴脂肪性肝炎患者血清VDR、纤维化因子及纤维化微小RNA的影响。
- 作者认为该试验为首个相关随机对照试验,结果将为维生素D补充控制NAFLD肝纤维化的有效性提供临床证据。
研究设计与样本
- 随机临床试验研究方案,计划招募46例NAFLD患者。
- 按性别和BMI区组匹配后随机分配至每日4000 IU维生素D组或安慰剂组,干预12周。
- 于研究基线及试验结束时检测血清纤维化MiR、层粘连蛋白、IV型胶原、透明质酸、维生素D、VDR、钙、血糖、血清胰岛素、血脂谱及肝脏标志物(ALT、AST、总胆红素、直接胆红素、间接胆红素)。
- 采用HOMA-IR和QUICKI方程评估胰岛素抵抗和胰岛素敏感性。
关键数值与推荐
- 干预剂量为维生素D 4000 IU/日或安慰剂,持续12周。
- 测量体重、身高和腰围。
- 检测血清纤维化MiR、层粘连蛋白、IV型胶原、透明质酸、维生素D、VDR、钙、血糖、血清胰岛素、血脂谱及肝脏标志物。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been suggested that vitamin D and its receptors involve in suppressing fibrogenic signaling in non-alcoholic fatty liver disease (NAFLD). However, the effect of vitamin D supplementation on fibrogenic factors has not been investigated in NAFLD individuals with steatohepatitis. This study was designed to examine the effects on vitamin D supplementation on serum levels of vitamin D receptor (VDR), fibrogenic factors, and fibrogenic microRNAs (MiR) in NAFLD patients. METHODS: Forty-six NAFLD patients will be recruited in this study. After block matching for sex and BMI, they will be randomly assigned to receive 4000 IU/day vitamin D or placebo for 12 weeks. Weight, height, and waist circumference will be measured. Determination of serum fibrogenic MiRs, laminin, collagen type IV, hyaluronic acid, vitamin D, VDR, calcium, blood glucose, serum insulin, lipid profile, liver markers (ALT, AST, total, direct, and indirect bilirubin) will be done at study baseline and at the end of the trial. Insulin resistance and insulin sensitivity will be determined using the HOMA-IR and QUICKI equation. DISCUSSION: This is the first randomized controlled trial that will determine the effect of vitamin D supplementation on serum levels of VDR, fibrogenic factors, and fibrogenic MiRs in NAFLD patients. The results of this trial will provide clinical evidence on the effectiveness of vitamin D supplementation in controlling liver fibrosis in NAFLD patients. TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT201405251485N13 . Registered on 14 March 2017.
引用
- Ebrahimpour-Koujan S, Sohrabpour AA, Foroughi F, et al. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial. Trials. 2019. PMID: 30832722. doi:10.1186/s13063-019-3241-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。